News

Updated results to the phase 3 CHAMPION-NMOSD trial of ravulizumab showed significantly lower HAI score worsening following treatment.

The medical director of the Rocky Mountain Movement Disorders Center talked about the motivations of the phase 2 study on ANX005 for Huntington disease at the 2023 AAN Annual Meeting. [WATCH TIME: 3 minutes]

FDA-approved for adults with generalized myasthenia gravis in 2016, eculizumab continued to show promising efficacy and safety responses in adolescents with the disease, regardless of on concomitant use of IVIG.

The neurologist at Montefiore Medical Center, Albert Einstein College of Medicine, provided insight on the need to improve online resources that provide epilepsy surgery information to patients. [WATCH TIME: 4 minutes]

After 228 weeks of treatment, annualized relapse rates favored twice-daily 75 mg dosing of evobrutinib vs once-daily.

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine spoke about preserving brain function through medical, sociopolitical, and educational efforts as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Neurology.

The majority of treatment-emergent adverse events from IPX203 were mild or moderate in nature, and occurred within the first 90 days of treatment.

Treatment with ALZ-801, an investigational agent in development for Alzheimer disease, resulted in more than 40% reduction in plasma p-tau181 at the end of the 12-month analysis.

The associate professor of neurology and director of the Penn Epilepsy Center at the University of Pennsylvania talked about the potential of using artificial intelligence in the field of neurology as part of an upcoming session at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]

There were no observed tolebrutinib dose effect for treatment-emergent adverse events in the double-blind portion, as well as no new safety signals seen for those who crossed over in the open-label extension.

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about the importance of vascular health in preventing cognitive impairment as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]

Rozanolixizumab has shown promising effects as a potential treatment for myasthenia gravis, as explained by high response rates on MG Activities of Daily Living and other measures.

Neurology News Network for the week ending April 22, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 21, 2023.

The cofounder and chief product development officer of Zevra Therapeutics talked about the phase 1 clinical trial of KP1077 for narcolepsy and potentially using it to treat other conditions. [WATCH TIME: 5 minutes]

After 90 days, investigators found that tenecteplase was not associated with improvements in functional outcome, nor did it differ from placebo on mortality.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert Zivadinov, MD, PhD. [LISTEN TIME: 30 minutes]

NMOSD-related optic neuritis represented the strongest predictive risk factor of failure to attain visual recovery of at least 0.3 logMAR, with an odds ratio of 10.47.

Resilience was positively correlated with quality of life in patients with narcolepsy type 1, according to a recent published study.

Greater cumulative exposure to HbA1c concentrations in the range of 6% to less than 8%, targets proposed by most geriatrics’ guidelines for healthier older people, were associated with lower hazard of dementia.

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about brain health in relation to vascular health ahead of the 2023 AAN annual meeting. [WATCH TIME: 3 minutes]

After showing promise in a phase 2 assessment, Taisho Pharmaceutical’s TS-142 will be assessed in a long-term study of 300 patients with the sleeping disorder.

Collectively, the results suggested that multiple sclerosis and migraine may co-occur because they share several genetic variants, rather than migraine causing MS.

Andrew Siderowf, MD, director of the Parkinson disease and movement center at the University of Pennsylvania, talked about available therapeutics and potential future therapies in research for Parkinson disease.

An immunology fellow at Brigham and Women’s Hospital provided perspective on the positive impacts a new diagnostic criterion for MOGAD brings to the clinical community. [WATCH TIME: 4 minutes]

Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.

The research fellow at the Neuroimmunology Clinic and Research Laboratory, Massachusetts General Hospital and Harvard Medical School, talked about his research of cell function in NMOSD to be presented at the upcoming AAN annual meeting. [WATCH TIME: 6 minutes]

The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided detail on an educational course that examined medication management for Parkinson disease psychosis.

Sheryl Lapidus, MA, senior director of patient advocacy at Horizon Therapeutics, talked about the findings from a recently conducted patient survey on NMOSD and the importance of advocacy in the field.